Cost Effectiveness, Chemotherapy, and the Clinician
Published In: Breast Cancer Research and Treatment, v. 114, no. 3, April 2009, p. 597-598
Posted on RAND.org on April 01, 2009
Economic evaluations of health care can be used by policy makers and other decision makers to compare the cost effectiveness of different treatment strategies and to make decisions about the allocation of scarce resources, such as dollars spent on health care. This commentary focuses on two journal articles address the cost effectiveness of docetaxel, doxorubicin and cyclophosphamide (TAC) compared to 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in the adjuvant treatment of breast cancer using data from a clinical trial, BCIRG 001 Both studies found that, despite the higher costs of TAC, the greater efficacy of this regimen in patients enrolled in BCIRG 001 led to a favourable cost effectiveness ratio.